RESEARCH ARTICLE

Midline Involvement as a Risk Factor for Vulvar Cancer Recurrence

Jekaterina Stankevica¹, Ronalds Macuks¹*, Ieva Baidekalna¹, Simona Donina²

Abstract

Objective: This observational study was to identify risk factors for vulvar cancer recurrence. Materials and Methods: In the study 107 patients with primary vulvar cancer were analyzed. Surgical treatment consisted of radical excision of the primary tumor in combination with unilateral or bilateral superficial and deep inguinofemoral lymphadenectomy through separate incisions. Patients with deeper tumor invasion >1 mm or wider than 2 cm and/or groin lymphnode metastases were referred for adjuvant radiotherapy. Those with large primary vulvar tumors received neoadjuvant radiotherapy of 30Gy followed by surgical treatment and adjuvant radiotherapy. Results: Most of patients had only primary radiotherapy to the vulva and inguinal lymph nodes and only 34.5% of patients were eligible for surgical treatment. In 5 year follow-up period 25.2% (27) patients were alive without the disease, 15.0% (16) were alive with the disease and 59.8% (64) were dead. 60.7% (65) patients experienced local recurrence and 2.8% (3) patients had distant metastases. Median survival for patients without recurrent disease was 38.9±3.2 months and 36.0±2.6 months with no statistically significant difference. Patients with early stage vulvar cancer had longer mean survival rates-for stage I 53.1±3.4 months, 38.4±4.4 months for stage II and 33.4±2.6 and 15.6±5.2 months for patients with stage III and stage IV vulvar cancer, respectively. The only significant prognostic factor predicting vulvar cancer recurrence was involvement of the midline. Conclusions: Patients having midline involvement of vulvar cancer has lower recurrence risk, probably because of receiving more aggressive treatment. There is a tendency for lower vulvar cancer recurrence risk for patients over 70 years of age and patients who are receiving radiotherapy as an only treatment without surgery, but tendency for higher risk of recurrence in patients with multifocal vulvar cancer.

Keywords: Vulva - cancer - recurrence - midline involvement

Asian Pacific J Cancer Prev, 13 (10), 5237-5240

Introduction

It is estimated by American Cancer Society that 4,490 women will be diagnosed with and 950 women will die of cancer of the vulva in 2012 (Howlader et al., 2012). The median age at diagnosis for cancer of the vulva is 68 years of age and median age at death for cancer of the vulva is 79 years of age (Howlader et al., 2012). Treatment for early stage vulvar cancer consists of radical excision of the tumor with ipsilateral or bilateral inguinofoemoral lymphadenectomy. Most of vulvar cancer recurrences occur in inguinal region and very rarely in the primary site of tumor excision (Magrina et al., 1979; Kelley et al., 1992; Sidor et al., 2006; Hampl et al., 2009). Several studies have described inguinal lymph node recurrences in up to 2.4% of cases (Hacker et al., 1983; Bell et al., 2000; Rodolakis et al., 2000; Ate van der Zee et al., 2008). Groin lymph-node metastases have been discovered as a most significant prognostic factors for vulvar cancer recurrence with a 5-year survival of 70-93% in patients with negative inguinofoemoral lymph-nodes compared to 25-41% in patients with lymph-node metastases (Gadducci et al., 2006).

Objective of this observational study was to identify risk factors for vulvar cancer recurrence.

Materials and Methods

In the study 107 patients with primary vulvar cancer were analyzed. Surgical treatment consisted of radical excision of the primary tumor in combination with unilateral or bilateral superficial and deep inguinofoemoral lymphadenectomy through separate incisions. A unilateral tumor was defined as a lesion that does not cross the midline, with the medial margin of the tumor more than 1 cm from the midline structures. The primary tumor was excised with a margin of at least 1 cm of normal skin. Unilateral excision was performed for tumors less than 2 cm in the diameter and with a deeper invasion less than 1mm, unless involvement of labia minora and positive ipsilateral lymphnodes were detected. Patients with deeper tumor invasion >1 mm or wider than 2 cm and/or groin lymphnode metastases were referred for adjuvant radiotherapy. Patients with large primary vulvar

¹Department of Gynecology and Obstetrics of Riga Stradins University, ²Department of Immunology of Riga Eastern Clinical University Hospital Riga, Latvia  *For correspondence: r.macuks@gmail.com
Jekaterina Stankevica et al

Table 1. Patient Characteristics

| Mean age, years (range) | 72.5 (37-96) |
|-------------------------|--------------|
| Tumor locularity, % (n) | Unilocal 91.6 % (98) Multilocular 8.4 % (9) |
| Involvement of midline, % (n) | Involved 50.5 % (54) Not involved 49.5 % (53) |
| Metastatic lymphnodes, % (n) | Ipsilateral 29.0 % (31) Bilateral 23.3 % (25) Contralateral 2.8 % (3) No metastases 44.9 % (48) |
| FIGO stage, % (n) | Stage I 17.8 % (19) Stage II 19.6 % (21) Stage III 58.9 % (63) Stage IV 3.7 % (4) |

FIGO stage: I = early stage, II = mid stage, III = late stage, IV = very late stage.

Table 2. Treatment Characteristics

| Surgical treatment only | Radical vulvectomy 33.6 % (36) Radical excision 0.9 % (1) |
|-------------------------|-------------------------------------------------------------|
| Inguinal lymphadenectomy | Bilateral 8.5 % (9) Unilateral 6.5 % (7) |
| Radiotherapy            | Radiotherapy only 64.5 % (69) As adjuvant treatment 31.8 % (34) No radiotherapy 3.7 % (4) |

Table 3. Risk Factors Predicting Vulvar Cancer Recurrence

| Risk factors          | HR (95% CI) | p     |
|-----------------------|------------|-------|
| Age, > 70 years       | 0.61 (0.36-1.05) | 0.07  |
| Multilocular leasion vs. Unilocular leasion | 1.91 (0.91-4.01) | 0.08  |
| Involvement of midline vs. lateral leasion | 0.46 (0.28-0.76) | 0.02  |
| Lymphnode metastases vs. no metastases | 0.83 (0.51-1.36) | 0.46  |
| Inguinal lymphadenectomy | 0.75 (0.40-1.40) | 0.36  |
| Preoperative and postoperative radiotherapy | 1.66 (0.98-2.81) | 0.06  |
| Late stage (FIGO III and IV) vs. early stage (FIGO I and II) cancer | 0.67 (0.40-1.10) | 0.12  |

Results

All patients had squamous cell carcinoma. Most of them had stage III cancer with unilocular primary lesions involving midline and having metastases in the ipsilateral, contralateral or bilateral inguinal lymphnodes (Table 1). Most of patients had only primary radiotherapy to the vulva and inguinal lymphnodes and only 34.5% of patients were eligible for surgical treatment. In 5 year follow-up period 25.2% (27) patients were alive without the disease, 15.0% (16) were alive with the disease and 59.8% (64) were dead. 60.7% (65) patients experienced local recurrences and 2.8% (3) patients had distant metastases. Median survival for patients without recurrent disease was 38.9±3.2 months and 36.0±2.6 months for patients with local recurrences and there was no statistically significant difference in 5-year overall survival of patients without local vulvar cancer recurrence (Figure 1).

Without local vulvar cancer recurrence (Figure 1).

Patients with early stage vulvar cancer had longer mean survival rates-for stage I 53.1±3.4 months, 38.4±4.4 months for stage II and 33.4±2.6 and 15.6±5.2 months for patients with stage III and stage IV vulvar cancer, respectively (Figure 2). The only significant prognostic factors predicting vulvar cancer recurrence was involvement of midline (Table 3).

Discussion

Results from the studies regarding prognostic factors for prognostic factors in vulvar cancer are controversial and can be explained by small sample size included in the retrospective studies and heterogenous treatment approaches (Iversen et al., 1980; Burger et al., 1995; Gonzalez et al., 2005). Potential risk factors for vulvar cancer recurrences include stage, tumour size, depth of invasion, tumor free margin, lymphovascular space invasion, age and nodal involvement. Although the importance of these risk factors is inconclusive and varies across the studies (Andreasson et al., 1985; Podratz et al., 1983; Hefler et al., 1999; Chan et al., 2007).
In this study, 107 patients with primary vulvar carcinoma were treated either with primary radical surgery following adjuvant radiotherapy or only radiotherapy in patients who were not appropriate for surgical treatment and were evaluated for risk factors of vulvar cancer recurrence.

In our study the only statistically significant risk factor preventing vulvar cancer recurrences was tumor involvement of midline (HR 0.46; p=0.02). This can be explained by more aggressive treatment of patients with midline involvement and thus better prognosis and less recurrences. Statistically there were no differences of vulvar cancer recurrences in patients with or without groin metastases (p=0.46), although this has been described in literature as a most significant risk factor predicting recurrent disease. In the study of Woelber et al. (2009) groin lymph node metastasis was the most important prognostic factor for disease-free and overall survival - patients with unilateral lymph node metastasis had a five-fold increased risk of recurrence compared to node-negative patients; in cases of bilateral lymph node involvement, this risk was 17 times higher.

Almost significant risk factors predicting vulvar cancer recurrence in our study was age over 70 years, tumor characteristics such as multilocular or unilocular and combined treatment of neoadjuvant radiotherapy following surgical treatment and adjuvant radiotherapy versus radiotherapy alone. There was a tendency for fewer vulvar cancer recurrences in patients over 70 years of age (HR 0.61; p=0.07). However, in the study of Woelber et al. vulvar cancer recurrences more often were found in elderly patients (Woelber et al., 2006).

Almost twice higher risk for vulvar cancer recurrence was observed in patients having multifocal disease in contrast to patient with unilocular lesion, although this factor didn’t reach statistical significance (HR 1.91, p=0.08). This finding can be explained by tumor lesions that were left undiagnosed and thus led to tumor recurrence.

The last risk factor found to be very close to reach statistical significance was neoadjuvant radiotherapy following surgery and adjuvant radiotherapy versus radiotherapy alone. There was a tendency for fewer vulvar cancer recurrences in patients over 70 years of age (HR 1.66; p=0.06). Such finding can be explained by larger tumors and more widespread dissemination in patients receiving pre- and postoperative radiotherapy. Although patients who are receiving radiotherapy as an only treatment are not appropriate for surgical treatment because of tumor spread, part of them are referred for radiotherapy because of co-morbidities and risk of wound dehiscence and not only because of wide tumor dissemination.

In our study we didn’t evaluate a number of involved groin lymphnodes and neither involvement of pelvic lymphnodes, but there are some studies not showing any association between the number of metastatic lymphnodes and the risk of recurrence, while in other analyses involvement of two or more nodes, extracapsular spread and large size of the metastases were predictive of vulvar cancer recurrence (Origoni et al., 1992; Paladini et al., 1994; Van et al., 1995; Lataifeh et al., 2004).

In the literature as a risk factors predicting vulvar cancer recurrence have been described also intracapsular lymph-node metastasis, lymphangio invasion and large primary tumours (Burger et al., 1995; Woelber et al., 2009; Oonk et al., 2010).

To get clear conclusions of vulvar cancer prognostic factors, large multicentric, prospective trial with uniform treatment approach is needed. In conclusions, patients having midline involvement of vulvar cancer has lower recurrence risk, probably because of receiving more aggressive treatment. There is a tendency for lower vulvar cancer recurrence risk for patients over 70 years of age and patients who are receiving radiotherapy as an only treatment without surgery, but tendency for higher risk of recurrence in patients with multifocal vulvar cancer.

Acknowledgements

Study was performed during PhD studies owing to project for PhD studies promotion in Latvia (P.Stradins University project number: 2009/0147/IDP/1.1.2.1.2/09/IP/IAA/009) and Latvian University project for early cancer diagnostics (project number: 2009/0220/IDP/1.1.1.2.0/09/APIA/IAAA/016).

References

Andreason B, Nyboe J (1985). Value of prognostic parameters in squamous cell carcinoma of the vulva. Gynecol Oncol, 22, 341-51.

Bell JG, Lea JS, Reid GC (2000). Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol, 77, 314-8.

Burger MP, Hollema H, Emanuels AG, et al (1995). The importance of the groin node status for the survival of T1 and T2 vulvar carcinoma patients. Gynecol Oncol, 57, 327-34.

Chan JK, Sugiyama V, Pham H, et al (2007). Margin distance and other clinicopathologic prognostic factors in vulvar carcinoma: A multivariate analysis. Gynecol Oncol, 104, 636-41.

Gadducci A, Cionini L, Romannia A, Fanucchi A, Genazzani AR (2006). Old and new perspectives in the management of highrisk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hemotol, 60, 227-41.

Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al (2005). Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol, 97, 828-33.

Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG (1983). Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol, 61, 408-12.

Hampl M, Kueppers V, Bender HG (2009). Single large inguinal lymph node metastasis in human papillomavirus-induced early invasive vulvar cancer of the anterior fourchette in two young women. Gynecol Obstet Invest, 67, 42-5.

Hefler L, Obermaier A, Tempfer C, et al (1999). Serum concentrations of squamous cell carcinoma antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer. Int J Cancer, 84, 299-303.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute.
Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.

Iversen T, Aalders JG, Christensen A, Kolstad P (1980). Squamous cell carcinoma of the vulva: A review of 424 patients, 1956-1974. Gynecol Oncol, 9, 271-9.

Kelley 3rd JL, Burke TW, Tornos C, et al (1992). Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy. Gynecol Oncol, 44, 240-4.

Lataifeh I, Carraro Nascimento M, Nicklin JL, et al (2004). Patterns of recurrence and disease-free survival in advanced squamous cell carcinoma of the vulva. Gynecol Oncol, 95, 701-5.

Magrina JF, Webb MJ, Gaffey TA, Symmonds RE (1979). Stage I squamous cell cancer of the vulva. Am J Obstet Gynecol, 134, 453-9.

Oonk MH, de Hullu JA, van der Zee AG (2010). Current controversies in the management of patients with early-stage vulvar cancer. Curr Opin Oncol, 22, 481-6.

Origoni M, Sideri M, Garsia S, Carinelli SG, Ferrari AG (1992). Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO. Gynecol Oncol, 45, 313-6.

Paladini D, Cross P, Lopes A, Monaghan JM (1994). Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva. Cancer, 74, 2491-6.

Podratz KC, Symmonds RE, Taylor WF, Williams TJ (1983). Carcinoma of the vulva: Analysis of treatment and survival. Obstet Gynecol, 61, 63-74.

Rodolakis A, Diakomanolis E, Voulgaris Z, et al (2000). Squamous vulvar cancer: a clinically based individualization of treatment. Gynecol Oncol, 78, 346-51.

Sidor J, Diallo-Danebrock R, Eltze E, Lelle RJ (2006). Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature. BMC Cancer, 6, 157.

Van der Velden J, van Lindert AC, Lammes FB, et al (1995). Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva. The impact on recurrence and survival. Cancer, 75, 2885-90.

Van der Zee AG, Oonk MH, De Hullu JA, et al (2008). Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol, 26, 884-9.

Woelber L., Mahner S., Voelker K., et al (2009). Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res, 29, 545-52.

Woolderink JM, de Bock GH, de Hullu JA, et al (2006). Patterns and frequency of recurrences of squamous cell carcinoma of the vulva. Gynecol Oncol, 103, 293-9.